19 US 8,765,432, US 11,819,531, AU Patent No. 2010330727, BR Patent No. 1120120145568, CA Patent No. 2783615, CA Patent No. 3039426, EP Patent No. 2512462, EP Patent No. 3254678, EP Patent No. 3659591, CN Patent No. ZL201080062252.7, HK Patent No. 1247828, IN Patent No. 319269, JP Patent No. 5760007, JP Patent No. 5990629, JP Patent No. 6416832, JP Patent No. 6777706, MX Patent No. 346423, MX Patent No. 374020, KR Patent No. 10- 1852044, MO Patent No. J/002943, and foreign applications in certain jurisdictions claiming priority to PCT/US2010/061358 5/10/2030 Representative claims include copolymers and methods of making copolymers (ABC Platform specific f ally) US 10,702,608, US 11,590,235, EP Patent No. 3041513, JP Patent No. 6463361, JP Patent No. 6732056, JP Patent No. 7232796, and foreign applications in certain jurisdictions claiming priority to PCT/US2014/054622 12/21/2034 Representative claims include polymers and method of making polymers US 11,066,465, US Appl. No. 17/301599, JP Patent No. 7088454, MX Patent No. 407292, RU Patent No. 2744860, and foreign applications in certain jurisdictions claiming priority to PCT/US2016/069336 12/29/2036 Representative claims include antibody and antibody conjugate, and methods of making and using the conjugates US Appl. No. 17/066856, US Appl. No. 18/504723, and foreign applications in certain jurisdictions claiming priority to PCT/US2020/055074 10/9/2040 Representative claims include method of treating an eye disorder using the antibody conjugates US Appl. No. 18/555122 and EP application claiming priority to PCT/US2022/024598 4/13/2042 Representative claims include method of treating an eye disorder using the antibody conjugates US Appl. No. 18/166755 and PCT Application No. PCT/US2023/062322 2/9/2043 Representative claims include method of purifyi f ng the antibody conjugates PCT Application No. PCT/US2023/074805 9/21/2043 Representative claims include methods of preparing a protein solution or therapeutic formulation US Appl. No. 16/290128 and foreign applications in certain jurisdictions claiming priority to PCT/US2019/020418 3/1/2039 Representative claims include fusion proteins and conjugates thereof, and methods of making and using the fusion proteins and the conjugates US Appl. No. 17/997866 and foreign applications in certain jurisdictions claiming priority to PCT/US2021/031194 5/6/2041 Representative claims include method of treating a disorder related to an infection or a systemic inflammatory condition using fusion proteins and conjugates thereof PCT Application No. PCT/US2023/082545 12/5/2043 Representative claims include formulations of a fusion protein and conjugates thereof, and methods of producing the same